It took a 3-year strug­gle, but No­var­tis fi­nal­ly gets a green light on their copy­cat to Am­gen's big block­buster

Over three years af­ter the first re­jec­tion and less than three months af­ter the last one, No­var­tis has fi­nal­ly earned FDA ap­proval for its biosim­i­lar to Am­gen’s $4 bil­lion can­cer drug Neu­las­ta. And they’re call­ing it Ziex­ten­zo.

Un­like the 2016 and 2019 re­jec­tions — both of which the Swiss gi­ant tucked in as a line item on a quar­ter­ly re­port — No­var­tis an­nounced the ap­proval in a state­ment Tues­day morn­ing.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.